What is Bio-Path Holdings, Inc. (BPTH) stock price today?

Bio-Path Holdings, Inc. (BPTH) is currently trading at $0.04, up 0% today.

What is BPTH P/E ratio?

Bio-Path Holdings, Inc.'s P/E ratio is -0.05. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is BPTH return on equity (ROE)?

Bio-Path Holdings, Inc.'s return on equity (ROE) is 76.46%, indicating how efficiently the company generates profit from shareholders' equity. This is considered high quality.

What is Bio-Path Holdings, Inc.'s market cap?

Bio-Path Holdings, Inc. has a market capitalization of $355002.

OTC · Biotechnology

Bio-Path Holdings, Inc. (BPTH) Stock

$0.04 +0.00% OTC: BPTH Healthcare

Bio-Path Holdings, Inc. is a U.S.-based pharmaceutical company focused on developing RNAi nanoparticle drugs for oncology, with programs spanning both clinical and preclinical stages.

Valuation

Metric	Value
Price	$0.04
Market Cap	$355002
P/E Ratio	-0.05
P/B Ratio	-0.04
P/S Ratio	0.00
EPS (TTM)	$-1.10
52-Week High	$0.16
52-Week Low	$0.01
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	76.46%
ROA	-899.85%
ROCE	63.58%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	-0.06
Current Ratio	0.07

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-10.0M	$-14.0M	$-16.0M	$-12.0M	$-8.0M
Net Profit	$-10.0M	$-14.0M	$-16.0M	$-10.0M	$-9.0M
EPS	$-31.04	$-38.03	$-33.64	$-4.12	$-1.10
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$27.0M	$16.0M	$3.0M	$4.0M	$1.0M
Total Liabilities	$1.0M	$2.0M	$3.0M	$4.0M	$9.0M
Cash	$24.0M	$10.0M	$1.0M	$1.0M	$0
Borrowings	$0	$0	$0	$0	$0

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-10.0M	$-15.0M	$-12.0M	$-11.0M	$-2.0M
Investing Cash Flow	$0	$0	$0	$0	$0
Financing Cash Flow	$4.0M	$0	$1.0M	$0	$0
Net Cash Flow	$10.0M	$-13.0M	$-9.0M	$0	$-1.0M
Free Cash Flow	$-10.0M	$-15.0M	$-12.0M	$-11.0M	$-2.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	-0.15
FCF Yield	-90.42%
Quick Ratio	0.07
Interest Coverage	-23.32
Return 1Y	-76.25%
Return 3Y	-99.84%
Return 5Y	-99.97%

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ELLXFElixinol Wellness Limited	$0.01	+0.00%	-0.28	$1.63M	0.00%
EMMAEmmaus Life Sciences, Inc.	$0.01	+0.09%	-0.09	$824010	0.00%
HXBMHelix BioMedix, Inc.	$1.02	+0.00%	-0.42	$229202	0.00%
IDCNIndocan Resources Inc.	$0.00	—	—	$74079	0.00%
ORGSOrgenesis Inc.	$0.11	-72.50%	-0.06	$568618	0.00%

About Bio-Path Holdings, Inc.

Bio-Path Holdings, Inc. is a U.S.-based pharmaceutical company focused on developing RNAi nanoparticle drugs for oncology, with programs spanning both clinical and preclinical stages. Its innovative product development is centered around the DNAbilize platform, a drug delivery and antisense technology that employs a P-ethoxy modified deoxyribonucleic acid (DNA) backbone. This modification is specifically engineered to shield the DNA from premature degradation. The company's lead drug candidate, prexigebersen, is presently in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. Additionally, Bio-Path is advancing Liposomal Bcl-2 for refractory/relapsed lymphoma and chronic lymphocytic leukemia. Another promising asset, Liposomal STAT3, is in preclinical development, targeting pancreatic cancer, non-small cell lung cancer, and AML. Furthermore, prexigebersen-A is under development for various solid tumors. Bio-Path Holdings, Inc., founded in 2007, is headquartered in Bellaire, Texas.

Bio-Path Holdings, Inc. is headquartered in US.

Bio-Path Holdings, Inc. (BPTH) stock trades at $0.04 with a market capitalization of $355002. The stock is valued at a price-to-earnings (P/E) ratio of -0.05, price-to-book of -0.04, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.01 and $0.16, and currently trades 75.0% below its 52-week high.

On profitability, Bio-Path Holdings, Inc. generates a return on equity (ROE) of 76.46% — well above the market average, a sign of a high-quality business, return on capital employed of 63.58%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.biopathholdings.com